Hep C - Vertex Drug Shows Promise in Hepatitis C

Vertex Drug Shows Promise in Hepatitis C
RedNova - Jan 10 2:56 PM
New data from a phase Ib study show that Vertex Pharmaceutical's VX-950 dosed in combination with pegylated interferon alfa-2a, achieved a rapid and dramatic reduction in virus levels in genotype 1 patients with chronic hepatitis C infection.Save to My Web

Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program
[Press Release] PR Newswire via Yahoo! Finance - Jan 18 4:00 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin Anti-Viral for the treatment of chronic hepatitis C virus infection .Save to My Web

Older Hepatitis C Patients Prove Difficult to Treat
RedNova - Jan 06 7:52 PM
Combination therapy in older hepatitis C patients results in more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits, according to a recent study carried out in Japan.Save to My Web

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV
FinanzNachrichten - Jan 12 11:38 PM
AMSTERDAM, Netherlands, Jan. 13 /PRNewswire-FirstCall/ -- Schering-Plough ( Nachrichten / Aktienkurs ) announced today that it is initiating a large multinational clinical trial to evaluate the use of low-dose PEG-INTRON(R) (peginterferon alfa-2b) maintenance monotherapy in preventing or delaying hepatitis C disease progression and thus potentially reducing the occurrence of clinical events such Save to My Web